Notice ID: 75N95024Q00564
The Therapeutic Development Branch (TDB) in the intramural Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH) was established to enable preclinical development through collaborative partnerships. In alignment with accomplishing the Center’s mission, the Branch needs to conduct a portfolio impact analysis, from its inception in 2010 to present. The goal is to capture key metrics and evaluate the program’s research outcomes, including analyzing the economic and other quantitative and qualitative impact measures on further research and development and healthcare. TDB requires the expertise of a firm capable of conducting such types of specialized impact analyses of novel therapeutics and related technologies. The results of this analysis will be used by Branch leadership to inform future research policy and priorities.
Specific Requirements
- Design an appropriate survey instrument and relevant analysis model(s) to gather and analyze the necessary quantitative and qualitative information.
- the methods utilized must be appropriate for and compatible with analysis of various outcome measures related to preclinical and clinical research and development (R&D) in support of novel therapeutics and related biomedical technologies.
- the model(s) should be able to analyze the quantitative and qualitative data to be gathered, and address the direct, indirect and induced impacts of the R&D activities (e.g., Impact Analysis for Planning (IMPLAN)).
- Prior to launching the data collection phase, the survey instrument will be discussed with and agreed to by the TDB staff.
- Gather publicly available data and conduct surveys / interviews with collaborators and key partners (estimated 100 nominated partners / projects) to gather the necessary information to be analyzed.
- Analyze the data with the appropriate analysis tool(s) and present the information in an acceptable format that clearly conveys the outcome of the survey with respect to the subject area.
- Generate a report and presentation slides to communicate the results in a manner appropriate for consumption by multiple audiences, including NCATS leadership, advisory groups, and the general public.
- The report and presentation must articulate the methods used, results obtained, and analyses generated.
- Generate impact stories / narratives based on the findings for up to four (4) exemplar drug development project case studies.
The period of performance is nine months, anticipated to be September 24, 2024 – June 24, 2025. The anticipated award date is September 23, 2024.
Not Yet a Premium Partner/Sponsor? Learn more about the OS AI Premium Corporate and Individual Plans here. Plans start at $250 annually.